奥曲肽联合前列地尔治疗肝硬化合并肝肾综合征的疗效分析  

Clinical Efficacy of Octreotide Combined with Alprostadil in the Treatment of Cirrhosis with Hepatorenal Syndrome

作　　者：付景[1] 郭冬梅[1] 李庆芝[1] 刘增福[1] 贺迎春 FU Jing;GUO Dong-mei;LI Qing-zhi;LIU Zeng-fu;HE Ying-chun(Department of Gastroenterology, Heze Municipal Hospital, Heze, Shandong Province, 274000 China)

机构地区：[1]山东省菏泽市立医院消化内科,山东菏泽274000

出　　处：《中外医疗》2019年第10期106-108,共3页China & Foreign Medical Treatment

摘　　要：目的探讨奥曲肽联合前列地尔治疗肝硬化合并肝肾综合征的临床疗效。方法方便选取2015年2月—2018年1月期间该院收治的90例肝硬化合并肝肾综合征患者,根据治疗方法分为单用奥曲肽组、单独前列地尔组和联合治疗组,每组各30例。分析比较三组患者的临床疗效、治疗前后的肝肾功能变化和临床症状改善情况。结果联合治疗组患者的治疗有效率高于单用前列地尔组(66.67%vs 93.33%,χ~2=6.667, P=0.010)和单用奥曲肽组(70.00%vs93.33%,χ~2=5.455, P=0.020);治疗后,联合治疗组患者的SCr、BUN、24 h尿量和ALT水平分别为(109.65±15.17)μmol/L、(9.37±2.00)mmol/L、(1639.45±256.53)mL、(99.78±20.17)U/L,单用前列地尔组患者的SCr、BUN、24h尿量和ALT水平分别为(120.17±15.39)μmol/L、(11.59±1.63)mmol/L、(1 238.94±263.17)m L、(110.04±19.30)U/L,单用奥曲肽组患者的SCr、BUN、24h尿量和ALT水平分别为(129.23±16.24)μmol/L、(11.49±1.54)mmol/L、(1267.95±307.26)m L、(114.32±23.80)U/L,联合治疗组患者的Cr、BUN、ALT水平单用前列地尔组和单用奥曲肽组(t=2.666、4.713、2.013;4.826、4.600、2.553,P=0.010、0.000、0.049、0.000、0.000、0.013),24 h尿量高于单用前列地尔组和单用奥曲肽组(t=5.969、5.084,P=0.000、0.000)。结论奥曲肽联合前列地尔治疗能显著改善肝硬化合并肝肾综合征患者的肝肾功能,疗效显著。Objective To investigate the clinical efficacy of octreotide combined with alprostadil in the treatment of cirrhosis with hepatorenal syndrome. Methods Convenient select 90 patients with cirrhosis and hepatorenal syndrome admitted to our hospital from February 2015 to January 2018 were enrolled. According to the treatment, octreotide group, alprostadil group and combination therapy group were used. 30 cases each. The clinical efficacy of the three groups of patients, the changes of liver and kidney function before and after treatment and the improvement of clinical symptoms were compared. Results Patients in the combination group were more effective than the alprostadil group (66.67% vs 93.33%,χ^2=6.667, P=0.010) and the octreotide group alone (70.00% vs 93.33%,χ2=5.455, P=0.020);After treatment, the SCr, BUN, 24h urine volume and ALT levels in the combination group were (109.65±15.17)μmol/L,(9.37±2.00) mmol/L,(1639.45±256.53) mL,(99.78± 20.17) U/L, SCr, BUN, 24h urine volume and ALT levels in patients with alprostadil alone were (120.17±15.39)μmol/L,(11.59±1.63) mmol/L,(1238.94±263.17) mL, respectively.(110.04±19.30) U/L, Cr, BUN, 24h urine volume and ALT levels in patients with octreotide alone were (129.23±16.24)μmol/L,(11.49±1.54) mmol/L,(1 267.95±307.26) mL,(114.32±23.80) U/L, The levels of SCr, BUN, and ALT in the combination group were only in the alprostadil group and the octreotide group (t=2.666, 4.713, 2.013;4.826, 4.600, 2.553, P=0.010, 0.000, 0.049;0.000, 0.000 , 0.013), 24 h urine volume was higher than the alprostadil group alone and the octreotide group alone (t=5.969, 5.084, P=0.000, 0.000). Conclusion Octreotide combined with alprostadil can significantly improve liver and kidney function in patients with cirrhosis and hepatorenal syndrome, and relieve its clinical symptoms.

关 键 词：奥曲肽 前列地尔 肝硬化 肝肾综合征 临床观察 

分 类 号：R575.2[医药卫生—消化系统] R692[医药卫生—内科学]